MDMA Therapy Training Program

The MDMA Therapy Training Program is a clinical training program that facilitates learning in the theory, skills, and practice of MDMA-assisted therapy. The theoretical approach is based on a philosophy that every person has within them an intrinsic wisdom and ability to heal, and that this inner healing wisdom blossoms naturally in an environment of safety and support.

 

About the Program

The MDMA Therapy Training Program was established in 2012 within the Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) nonprofit founded in 1986. The training program is now operated by MAPS Public Benefit Corporation (MAPS PBC), a psychedelic pharmaceutical public benefit corporation wholly owned by MAPS. As of June 2021, the MDMA Therapy Training Program has trained over 1,400 clinicians in dozens of cohorts across the United States, Israel, Canada, Netherlands, United Kingdom, and virtually. Trainees have come from around the world, representing more than a dozen countries and dozens of cultures.

Reports from previous participants in the MDMA Therapy Training Program:

“This training has been a peak experience in my professional career!”

“I arrived with the intention to be open, curious, embodied, and unattached to outcomes. And learn, I did- in the most enriching and inspiring ways.”

“I didn’t quite know how much I longed for a diverse community of loving, supportive, and like-minded professionals until I found myself in the middle of one. To share a common mission and sense of purpose around healing is profoundly meaningful. For me, this was a coming home.”

About MDMA-Assisted Therapy Clinical Trials and Regulatory Approval Process

MAPS PBC is conducting international clinical trials investigating MDMA-assisted therapy as a treatment for Posttraumatic Stress Disorder (PTSD) and other conditions. The study results will be used to support the application of MDMA-assisted therapy for regulatory approval in multiple countries globally. MDMA-assisted therapy is an investigational treatment and is not yet approved for use outside of research. Phase 3 MDMA-assisted therapy clinical research has demonstrated that 67% of participants in the MDMA group no longer qualified for a PTSD diagnosis two months after treatment, compared to 32% in the placebo group. Please visit Publications to learn more about the latest published study results and MAPS-sponsored clinical trials.

The primary requirements for delivery of MDMA-assisted therapy include:

  • Qualified medical professionals
  • Qualified behavioral health practitioners
  • Appropriate facilities for conducting MDMA-assisted therapy and storing controlled substances
  • Approved research protocol or sanctioned legal status of MDMA-assisted therapy

These requirements vary by region, regulatory agency, and protocol. Psychedelic therapy is a growing field defining and refining professional standards, ethical guidelines, scope of practice and scope of competence. The exact qualifications and credentialing requirements that may be required for practitioners, if and when regulatory approval is achieved, are not known and will be determined by the regulatory agency, the study Sponsor, community members and the professional field. Candidates with active licenses to conduct psychotherapy may be the most likely to qualify as practitioners of psychedelic therapies in the future, however this will not be determined until later in the drug development process.

MAPS PBC cannot predict regulatory approval in the drug development process. Participation in the MDMA Therapy Training Program is not a guarantee or promise of employment, career trajectory, or the future status of MDMA-assisted therapy. If Phase 3 clinical trials continue to demonstrate safety and efficacy of the treatment and if regulatory agencies approve MDMA-assisted therapy as a legal treatment, a primary factor of patient access will be the number and availability of qualified practitioners ready to enter practice. Due to the unpredictable nature of clinical research, we understand that many qualified practitioners may wish to wait until regulatory approval is granted, and opportunities to deliver MDMA-assisted therapy are confirmed, before investing in their training with the MDMA Therapy Training Program.

MDMA Therapy Training Program Outline

100-hour Program

This program consists of live presentations, video case presentations, role play, scenario enactments, self-reflection activities, group and dyad activities, reading, writing, coursework, and creative projects.

Small groups, facilitated by MAPS Trainers, meet regularly throughout the program and provide a container for discussion, integration, process, and practice. Trainers and assistants are available to support trainees throughout the program.

 

 

Culture and Community

The MDMA Therapy Training Program invites trainees to approach this modality with curiosity and a willingness to not know all the answers. The program also invites trainees to cultivate trust in their own inner healing wisdom, which can be used as a resource in the therapy room as well as throughout this training course, and of course in one’s personal life. This is a professional and personal development course and includes activities that invite trainees to reflect with vulnerability and authenticity. The Trainers and staff will do the same.

The program aims to create a community of learning that facilitates knowledge sharing, networking, and cultivating the wisdom of each person and the group. All staff and trainees are expected to act in a respectful, inclusive, and non-discriminatory manner, and to take responsibility for their actions.

The MDMA Therapy Training Program is committed to addressing mental health disparities in psychedelic therapy as well as trauma treatment, especially those facing the most marginalized communities. In a commitment to address the current lack of diversity in psychedelic research, qualified clinicians from and serving communities of color, LGBTQIA+, people with disabilities, military populations, and other marginalized or underrepresented communities are strongly encouraged to apply.

The MDMA Therapy Training Program advances equity and inclusion by providing opportunities and establishing fair practices to support a training and treatment environment free from discrimination on the basis of race, religious creed, color, national origin, ancestry, physical disability, mental disability, medical condition, genetic information, marital status, sex, gender, gender identity, gender expression, sexual orientation, military and veteran status. The organization also provides reasonable accommodations for qualified applicants with disabilities. The MDMA Therapy Training Program strives to establish and maintain an equitable and accessible training environment that is supportive and free from discrimination.

MAPS Public Benefit Corporation

Our Mission
Who We Are
Careers
News
FAQ
Contact Us

3141 Stevens Creek Blvd #40547
San Jose, CA 95117

Therapy Training

Overview
Application

MAPS PBC is a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS). MAPS is a 501(c)(3) non-profit research and educational organization.

Stay Up-to-Date about MDMA Therapy Training

You have Successfully Subscribed!